DE69812727D1 - Opioid-konjugate mit endogenen Trägerproteinen - Google Patents

Opioid-konjugate mit endogenen Trägerproteinen

Info

Publication number
DE69812727D1
DE69812727D1 DE69812727T DE69812727T DE69812727D1 DE 69812727 D1 DE69812727 D1 DE 69812727D1 DE 69812727 T DE69812727 T DE 69812727T DE 69812727 T DE69812727 T DE 69812727T DE 69812727 D1 DE69812727 D1 DE 69812727D1
Authority
DE
Germany
Prior art keywords
patient
conjugates
antinociceptive
conjugate
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812727T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Application granted granted Critical
Publication of DE69812727D1 publication Critical patent/DE69812727D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69812727T 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen Trägerproteinen Expired - Lifetime DE69812727D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
DE69812727D1 true DE69812727D1 (de) 2003-04-30

Family

ID=22057753

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69812727T Expired - Lifetime DE69812727D1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen Trägerproteinen
DE69804974T Expired - Lifetime DE69804974T2 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69804974T Expired - Lifetime DE69804974T2 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Country Status (9)

Country Link
EP (2) EP1007561B1 (de)
JP (2) JP2001522817A (de)
AT (2) ATE235513T1 (de)
AU (3) AU750387B2 (de)
CA (2) CA2301799C (de)
DE (2) DE69812727D1 (de)
ES (1) ES2173641T3 (de)
IL (1) IL135835A0 (de)
WO (3) WO1999024462A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1810832B (zh) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DK1105409T3 (da) * 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CN1698881A (zh) * 1999-05-17 2005-11-23 康久化学公司 病毒感染的长效融合肽抑制剂
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
ATE443714T1 (de) * 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
AU2002233082B2 (en) 2001-02-02 2005-11-10 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
WO2004066917A2 (en) 2003-01-17 2004-08-12 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
ES2347902T3 (es) 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
CA2955408A1 (en) * 2014-07-18 2016-01-21 Biocogent, Llc Compositions and methods comprising salicylates and polysalicylates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
EP1007561A2 (de) 2000-06-14
ATE216402T1 (de) 2002-05-15
WO1999024076A9 (en) 2000-06-08
JP2001522863A (ja) 2001-11-20
CA2301799A1 (en) 1999-05-20
AU1312799A (en) 1999-05-31
WO1999024074A3 (en) 1999-08-19
CA2301799C (en) 2007-08-07
WO1999024076A3 (en) 1999-08-19
AU750387B2 (en) 2002-07-18
EP1007561B1 (de) 2002-04-17
EP1028971A2 (de) 2000-08-23
ES2173641T3 (es) 2002-10-16
AU1519799A (en) 1999-05-31
IL135835A0 (en) 2001-05-20
CA2309205A1 (en) 1999-05-20
WO1999024462A3 (en) 1999-08-26
DE69804974D1 (de) 2002-05-23
WO1999024462A2 (en) 1999-05-20
DE69804974T2 (de) 2002-11-07
ATE235513T1 (de) 2003-04-15
JP2001522817A (ja) 2001-11-20
WO1999024076A2 (en) 1999-05-20
WO1999024074A2 (en) 1999-05-20
AU1385699A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
EP0276278B1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze
Ringsdorf Structure and properties of pharmacologically active polymers
Masquelier et al. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice
Urquhart et al. Rate-controlled delivery systems in drug and hormone research
CA2064689A1 (en) Stabilized protein or peptide conjugates
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
Sauer et al. Identification of linoleic and arachidonic acids as the factors in hyperlipemic blood that increase [3H] thymidine incorporation in hepatoma 7288CTC perfused in situ
Shechter et al. Reversible pegylation of insulin facilitates its prolonged action in vivo
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
WO1993016718A1 (en) Hepatoma treatment with somatostatin analogs
US20040248806A1 (en) Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
Basu et al. Enhanced intracellular delivery of doxorubicin by scavenger receptor‐mediated endocytosis for preferential killing of histiocytic lymphoma cells in culture
Wright et al. Local action of parathyroid hormone (1–34) and (1–84) at the parotid gland of sheep
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
8332 No legal effect for de